Introduction

S113  Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
      I. Raz, W.T. Cefalu, H. Ilkova, and S. Del Prato

I. Prevention and Progression of Diabetes

S115  Preventing Diabetes: Early Versus Late Preventive Interventions
      J. Tuomilehto and P.E.H. Schwarz

S121  Slowing Down the Progression of Type 2 Diabetes: We Need Fair, Innovative, and Disruptive Action on Environmental and Policy Levels!
      P.E.H. Schwarz and H. Riemenschneider

II. Diabetes Treatment Options

S127  Personalized Therapy by Phenotype and Genotype
      V. Lyssenko, C. Bianchi, and S. Del Prato

S137  Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
      A. Cahn and W.T. Cefalu

S146  Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back: Recommendations of the Israel National Diabetes Council
      O. Mosenzon, R. Pollack, and I. Raz

III. SGLT2 Therapy

S154  Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
      J.P.H. Wilding, S.P. Rajeev, and R.A. DeFronzo

S165  SGLT2 Inhibitors and the Diabetic Kidney
      P. Fioretto, A. Zambon, M. Rossato, L. Busetto, and R. Vettor

IV. Insulin Therapy

S172  New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
      E. Standl and D.R. Owen

S180  When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump
      O. Cohen, S. Filetti, J. Cotañeda, M. Maranghi, and M. Glandt

V. Recent Outcome Studies

S187  Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
      F. Giorgino, P.D. Home, and J. Tuomilehto

S196  Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis
      E. Mannucci, O. Mosenzon, and A. Avogaro

S205  Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
      M. Hanefeld, B.M. Frier, and F. Pistrosch

S210  Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS
      G. Schernthaner, A. Cahn, and I. Raz

S219  Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications
      B.J. Hoogwerf, D.H. Manner, H. Fu, E. Moscarelli, B.L. Gaydos, and R.J. Heine

VI. Cardiovascular Risk and Diabetes

S228  Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?
      G. Grassi, G. Mancia, and P.M. Nilsson

S234  What Should Be the Target Blood Pressure in Elderly Patients With Diabetes?
      A. Solini and E. Grossman

S244  Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
      R.M. Pollack, M.Y. Donath, D. LeRoith, and G. Leibowitz

S253  Remembering Statins: Do Statins Have Adverse Cognitive Effects?
      R. Bitzur

VII. Obesity

S260  Pharmacological Approaches in the Treatment and Maintenance of Weight Loss
      L. Van Gaal and E. Dirinck

S268  Revisiting the Role of BMI in the Guidelines for Bariatric Surgery
      G. Segal-Lieberman, P. Segal, and D. Dicker